Please use this identifier to cite or link to this item:
|Title:||An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells||Authors:||Uota, S.
Zahidunnabi Dewan, M.
|Issue Date:||Jan-2012||Citation:||Uota, S., Zahidunnabi Dewan, M., Saitoh, Y., Muto, S., Itai, A., Utsunomiya, A., Watanabe, T., Yamamoto, N., Yamaoka, S. (2012-01). An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells. Cancer Science 103 (1) : 100-106. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1349-7006.2011.02110.x||Abstract:||Adult T-cell leukemia (ATL) is a fatal T-cell malignancy associated with human T-cell leukemia virus type I infection. The aberrant expression of nuclear factor-κB (NF-κB) is considered to contribute to the malignant phenotype and chemo-resistance of ATL cells. Because of the poor prognosis of ATL, the development of new therapeutic strategies is direly needed. In the present study, we show that an IκB kinase 2 (IKK2) inhibitor, IMD-0354, efficiently inhibits the survival of CD4 +CD25 + primary ATL cells and prevents the growth of or induces apoptosis of patient-derived ATL cell lines. Assays of transcription with integrated forms of reporter genes revealed that IMD-0354 suppresses NF-κB-dependent transcriptional activity. Moreover, the daily administration of IMD-0354 prevents the growth of tumors in mice inoculated with ATL cells. Our results suggest that targeting IKK2 with a small molecule inhibitor, such as IMD-0354, is an attractive strategy for the treatment of ATL. © 2011 Japanese Cancer Association.||Source Title:||Cancer Science||URI:||http://scholarbank.nus.edu.sg/handle/10635/126707||ISSN:||13479032||DOI:||10.1111/j.1349-7006.2011.02110.x|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 11, 2020
WEB OF SCIENCETM
checked on Aug 3, 2020
checked on Jul 31, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.